Liver injury induced by herbal complementary and alternative medicine

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 715-735

  Navarro, Victor J ^a   Seeff, Leonard B ^b  

^a Division of Gastroenterology and Hepatology   (United States)

^b The Hill Group   (United States)

Author keywords

Causality assessment; Dietary supplements; Hepatotoxicity; Herbal; Regulatory

Indexed keywords

AMINO ACID; ANABOLIC AGENT; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CONJUGATED LINOLEIC ACID; CORTICOSTEROID; DAISAIKOTO; DICLOFENAC; DIETHYLSTILBESTROL; DIPHENHYDRAMINE; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; INDOMETACIN; ISONIAZID; KAVA; MINERAL; PHOSPHODIESTERASE V INHIBITOR; PROMETHAZINE; PYRROLIZIDINE ALKALOID; SILDENAFIL; TRIAMTERENE; USNIC ACID; VALERIAN; VITAMIN; WARFARIN;

ACTAEA RACEMOSA; ALOE VERA; ALTERNATIVE MEDICINE; BODY BUILDING; CHELIDONIUM; CHINESE MEDICINE; CHRONIC LIVER DISEASE; COMFREY; DIET SUPPLEMENTATION; DRUG CONTAMINATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; EPHEDRA SINICA; GERMANDER; GOOD MANUFACTURING PRACTICE; HUMAN; LAW; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MARIA AND VICTORINO SCALE; MORINDA CITRIFOLIA; NARANJO ADVERSE DRUG REACTION SCALE; PLACEBO EFFECT; REVIEW; ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD; SCORING SYSTEM; TEA; UNITED STATES; WEIGHT REDUCTION;

CAUSALITY ASSESSMENT; DIETARY SUPPLEMENTS; HEPATOTOXICITY; HERBAL; REGULATORY;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; DRUG-INDUCED LIVER INJURY; HUMANS; PLANT PREPARATIONS; UNITED STATES;

EID: 84884947670     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.006     Document Type: Review

References (171)

1. WHO. Traditional medicine. Fact sheet no. 134. December 2008. Available at:. http://www.who.int/mediacentre/factsheets/fs134/en/.
2. Blendon R.J., DesRoches C.M., Benson J.M., et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 2001, 161:805-810.
3. Robinson A., Cooper S. Trusted information sources: the preferred option for complementary and alternative medicine users. Complement Health Pract Rev 2007, 12:120.
4. Decker C., Huddleston J., Kosiborod M., et al. Self-reported use of complementary and alternative medicine in patients with previous acute coronary syndrome. Am J Cardiol 2007, 99:930-933.
5. Ostrow M.J., Cornelisse P.G., Heath K.V., et al. Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents. JAcquir Immune Defic Syndr Hum Retrovirol 1997, 15:115-120.
6. Seeff L.B., Curto T.M., Szabo G., et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 2008, 47:605-612.
7. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009, 69:1777-1798.
8. Zeller T., Muenstedt K., Stoll C., et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. JCancer Res Clin Oncol 2013, 139:357-365.
9. Eisenberg D.M., Kessler R.C., Foster C., et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. NEngl J Med 1993, 328:246-252.
10. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national study. JAMA 1998, 280:1569-1575.
11. Block G., Cox D., Madans J., et al. Vitamin supplement use, by demographic characteristics. Am J Epidemiol 1988, 127:297-309.
12. Koplan J.P., Annest J.L., Layde P.M., et al. Nutrient intake and supplementation in the United States (NHANES II). Am J Public Health 1986, 76:287-289.
13. Ervin R.B., Wright J.D., Kennedy-Stephenson J. Use of dietary supplements in the United States, 1988-1994. Vital Health Stat 11 1999, (244):i-iii. 1-14.
14. Radimer K., Bindewald B., Hughes J., et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004, 160:339-349.
15. Ni H., Simile C., Hardy A.M. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002, 40:353-358.
16. Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005, 27:1847-1858.
17. Timbo B.B., Ross M.O., McCarthy P.V., et al. Dietary supplements in a national survey: prevalence of use and reports of adverse events. JAm Diet Assoc 2006, 106:1966-1974.
18. Nahin R.L., Barnes P.M., Stussman B.J., et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007 2009, National Health Statistics Reports; no 18, National Center for Health Statistics, Hyattsville (MD).
19. Cavaliere C., Rea P., Lynch M.E., et al. Herbal supplement sales rise in all channels in 2009. HerbalGram 2010, 86:62-65.
20. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Rationale, design and conduct of the Drug Induced Liver Injury Network prospective study. Drug Saf 2009, 32:55-68.
21. Navarro V.J., Barnhart H.X., Bonkovsky H.L., et al. Herbal and dietary supplement induced hepatotoxicity in the U.S. Gastroenterology 2012, 142(5):S1. S-41. [Abstract #167].
22. Food and Drug Administration. Dietary supplements. Available at:. Accessed March 25, 2013. http://www.fda.gov/Food/DietarySupplements/default.htm.
23. Food and Drug Administration. Food guidance documents. Available at:. Accessed March 25, 2013. http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/default.htm.
24. Council for Responsible Nutrition (CRN). Available at:. Accessed March 25, 2013. http://www.crnusa.org/FDAunity/FDAManufacturerDietarySupplements121510.pdf.
25. Robinson A., McGrail M.R. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med 2004, 12(2-3):90-98.
26. Komes D., Belscak-Cvitanovic A., Horzic D., et al. Phenolic composition and antioxidant properties of some traditionally used medicinal plants affected by the extraction time and hydrolysis. Phytochem Anal 2011, 22:172-180. 2011.
27. Harkey M.R., Henderson G.L., Gershwin M.E., et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001, 73:1101-1106.
28. Ye F., Wang H., Jiang S., et al. Quality evaluation of commercial extracts of Scutellaria baicalensis. Nutr Cancer 2004, 49:217-222.
29. Centers for Disease Control and Prevention Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010, 59:224-229.
30. Black M., Mitchell J.E., Zimmerman H.J., et al. Isoniazid associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
31. Naranjo C.A., Busto U., Sellers E.M., et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
32. Sarma D.N., Barrett M.L., Chavez M.L., et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008, 6:469-484.
33. Teschke R., Schmidt-Taenzer W., Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality?. Pharmacoepidemiol Drug Saf 2011, 20:567-582.
34. Teschke R., Schulze J. Suspected herbal hepatotoxicity. Requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012, 35:1091-1097.
35. Danan G., Benichou C. Causality assessment of adverse reactions to drugs-I. A novel methods based on the conclusions of international consensus meetings; application to drug-induced liver injuries. JClin Epidemiol 1993, 46:1323-1330.
36. Maria V.A., Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology 1997, 26:664-669.
37. Rockey D.C., Seeff L.B., Rochon J., et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126.
38. Navarro V.J., Barnhart H.X., Bonkovsky H.L., et al. Diagnosing hepatotoxicity attributable to herbal & dietary supplements (HDS): test-retest reliability of a novel causality assessment tool. Jof Hepatol 2012, 56(S2):S536. [Abstract 1364].
39. Kneifel W., Czech E., Kopp B. Microbial contamination of medicinal plants. Planta Med 2000, 68:5-15.
40. Stickel F., Droz S., Patsenker E., et al. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. JHepatol 2009, 50:111-117.
41. Gray S.L., Lackey B.R., Tate P.L., et al. Mycotoxins in root extracts of American and Asian ginseng bind estrogen receptors alpha and beta. Exp Biol Med 2004, 229:560-568.
42. Saper R.B., Phillips R.S., Sehgal A., et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the internet. JAMA 2008, 300:915-923.
43. Wong M.K., Tan P., Wee Y.C. Heavy metals in some Chinese herbal plants. Biol Trace Elem 1993, 36:135-142.
44. Koh H.L., Woo S.O. Chinese propriety medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 2000, 23:351-362.
45. Au A.M., Ko R., Boo F.O., et al. Screening methods for drugs and heavy metals in Chinese patent medicines. Bull Environ Contam Toxicol 2000, 65:112-119.
46. Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 2002, 57:891-896.
47. Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003, 52:1361-1371.
48. Centers for Disease Control and Prevention Lead poisoning associated with use of Ayurvedic medication - five states. 2000-2003. MMWR Morb Mortal Wkly Rep 2004, 53:582-584.
49. Miller G.M., Streipp R. Astudy of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown. Leg Med (Tokyo) 2007, 9:258-264.
50. Guns E.S., Goldenberg S.L., Brown P.N. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol 2002, 9:1684-1688.
51. Oh W.K., Small E.J. Complementary and alternative therapies in prostate cancer. Semin Oncol 2002, 29:575-584.
52. Sovak M., Seligson A.L., Konas M., et al. Herbal composition of PC-SPES for management of prostate cancer: identification of active principles. JNatl Cancer Inst 2002, 94:1275-1281.
53. Fleshler N., Harvey M., Adomat H., et al. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. JUrol 2005, 174:636-641.
54. Teschke R., Wolff A., Frenzel C., et al. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 2012, 32:1543-1556.
55. Haupt H.A., Rovere G.D. Anabolic steroids: a review of the literature. Am J Sports Med 1984, 12:469-484.
56. Ishak K.G. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981, 1:116-128.
57. Timchec-Hariri A., Balali-Mood M., Aryan E., et al. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol 2012, 50:3826-3832.
58. Singh V., Rudraraju M., Carey E., et al. Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. JClin Gastroenterol 2009, 43:287200.
59. DesJardins M. Supplement use in the adolescent athlete. Curr Sports Med Rep 2002, 1:369-373.
60. Dodge T.L., Jaccard J.J. The effect of high school sports participation on the use of performance-enhancing substances in young adulthood. JAdolesc Health 2006, 39:367-373.
61. Avelar-Escobar G., Mendez-Navarro J., Ortiz-Olvera N., et al. Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes. Ann Hepatol 2012, 11:564-569.
62. Ramos R., Mascarenhas J., Duarte P., et al. Conjugated linoleic acid-induced toxic hepatitis: first case report. Dig Dis Sci 2009, 54:1141-1143.
63. Nortadas R., Barata J. Fulminant hepatitis during self-medication with conjugated linoleic acid. Ann Hepatol 2012, 11:265-267.
64. Skoulidis F., Alexander G.J., Davies S.E. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol 2005, 17:581-584.
65. Neff G.W., Reddy R., Durazo F.A., et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. JHepatol 2004, 41:162-164.
66. Estes J.D., Stolpman D., Olyaei A., et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003, 138:852-858.
67. Borum M.L. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol 2001, 96:1654-1655.
68. Nadir A., Agrawal S., King P.D., et al. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol 1996, 91:1436-1438.
69. Mimidis K.P., Papadopoulos V.P., Baltatzidis G., et al. Severe acute cholestasis caused by Teucrium polium. JGastrointestin Liver Dis 2009, 18:387-388.
70. Poon W.T., Chau T.L., Lai C.K., et al. Hepatitis induced by Teucrium viscidum. Clin Toxicol (Phila) 2008, 46:819-822.
71. Savvidou S., Goulis J., Giavazis I., et al. Herb-induced hepatitis by Teucrium polium L.: report of two cases and review of the literature. Eur J Gastroenterol Hepatol 2007, 19:507-511.
72. Starakis I., Siagris D., Leonidou L., et al. Hepatitis caused by the herbal remedy Teucrium polium L. Eur J Gastroenterol Hepatol 2006, 18:681-683.
73. Mazokopakis E., Lazaridou S., Tzardi M., et al. Acute cholestatic hepatitis caused by Teucrium polium L. Phytomedicine 2004, 11:83-84.
74. Polymeros D., Kamberoglou D., Tzias V. Acute cholestatic hepatitis caused by Teucrium polium (golden germander) with transient appearance of antimitochondrial antibody. JClin Gastroenterol 2002, 34:100-101.
75. Laliberté L., Villeneuve J.P. Hepatitis after the use of germander, a herbal remedy. CMAJ 1996, 154:1689-1692.
76. Mattei A., Rucay P., Samuel D., et al. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. JHepatol 1995, 22:597.
77. Mostefa-Kara N., Pauwels A., Pines E., et al. Fatal hepatitis after herbal tea. Lancet 1992, 340(8820):674.
78. Larrey D., Vial T., Pauwels A., et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992, 117:129-132.
79. Lambert J.D., Kennett M.J., Sang S., et al. Hepatotoxicity of high oral dose(-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 2010, 48:409-416.
80. Galati G., Lin A., Sultan A.M., et al. Cellular and invivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med 2006, 40:570-580.
81. Molinari M., Watt K.D., Kruszyna T., et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006, 12:1892-1895.
82. Martinez-Sierra C., Rendón Unceta P., Martin Herrera L. Acute hepatitis after ingestion of green tea. Med Clin (Barc) 2006, 27:119. [in Spanish].
83. Bonkovsky H.L. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006, 144:68-71.
84. Elinav E., Pinsker G., Safadi R., et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. JHepatol 2007, 47:514-520.
85. Schoepfer A.M., Engel A., Fattinger K., et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. JHepatol 2007, 47:521-526.
86. Chao S., Anders M., Turbay M., et al. Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol Latinoam 2008, 38:274-277.
87. Manso G., Lopez-Rivas L., Salgueiro M.E., et al. Continuous reporting of new cases in Spain supports the relationship between Herbalife products and liver injury. Pharmacoepidemiol Drug Saf 2011, 20:1080-1087.
88. Stevens T., Qadri A., Zein N.N. Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut. Ann Intern Med 2005, 1426:477-478.
89. Jones F.J., Andrews A.H. Acute liver injury associated with the herbal supplement Hydroxycut in a soldier deployed to Iraq. Am J Gastroenterol 2007, 102:2357-2358.
90. Shim M., Saab S. Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci 2009, 54:406-408.
91. Dara L., Hewett J., Kim J.K. Hydroxycut hepatotoxicity: a case series and review of the liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008, 14:6999-7004.
92. Fong T.L., Klontz K.C., Canas-Coto A., et al. Hepatotoxicity due to Hydroxycut: a case series. Am J Gastroenterol 2010, 105:1561-1566.
93. Food and Drug Administration. Available at:. Accessed February 25, 2013. http://www.fda.gov/oc/opacom/hottopics/hydroxycut/consumeradvisory.html.
94. Han D., Matsumaru K., Rettori D., et al. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 2004, 67:439-445.
95. Pramyothin P., Janthasoot W., Pongnimitprasert N., et al. Hepatotoxic effect of (+) usnic acid from Usnea siamensis Wainio in rats, isolated rat hepatocytes and isolated rat liver mitochondria. JEthnopharmacol 2004, 90:381-387.
96. Favreau J.T., Ryu M.L., Braunstein G., et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetrix. Ann Intern Med 2002, 136:590-595.
97. Durazo F.A., Lassman C., Han S.B., et al. Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 2004, 99:950.
98. Sanchez W., Maple J.T., Burgart L.J., et al. Severe hepatotoxicity associated with the use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006, 81:541-544.
99. Food and Drug Administration. Medical foods. Available at:. Accessed March 26, 2013. http://www.fda.gov/food/foodsafety/product-specificinformation/medicalfoods/default.htm.
100. Altavilla D., Squadrito F., Bitto A., et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol 2009, 157:1410-1418.
101. Chalasani N., Vuppalanchi R., Navarro V.J., et al. Acute liver injury due to Flavocoxid (Limbrel), a medical food for osteoarthritis. A case series. Ann Intern Med 2013, 156:857-860.
102. Linnebur S.A., Rapacchietta O.C., Vejar M., et al. Hepatotoxicity associated with Chinese skullcap contained in move free advanced dietary supplement: two case reports and review of the literature. Pharmacotherapy 2010, 30:750. 258e-62e.
103. Yang H.N., Kim D.J., Kim Y.M., et al. Aloe-induced toxic hepatitis. JKorean Med Sci 2010, 25:492-495.
104. Jacobsson I., Jönsson A.K., Gerdén B., et al. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiol Drug Saf 2009, 18:1039-1047.
105. Bottenberg M.M., Wall G.C., Harvey R.L., et al. Oral aloe vera-induced hepatitis. Ann Pharmacother 2007, 41:1740-1743.
106. Kanat O., Ozet A., Ataergin S. Aloe vera-induced acute toxic hepatitis in a healthy young man. Eur J Intern Med 2006, 17:589.
107. Rabe C., Musch A., Schirmacher P., et al. Acute hepatitis induced by an aloe vera preparation: a case report. World J Gastroenterol 2005, 11:303-304.
108. Kauma H., Koskela R., Mäkisalo H., et al. Toxic acute hepatitis and hepatic fibrosis after consumption of chaparral tablets. Scand J Gastroenterol 2004, 39:1168-1171.
109. Pittler M.H., Ernest E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003, 18:451-471.
110. Sheikh N.M., Philen R.M., Love L.A. Chaparral-associated hepatotoxicity. Arch Intern Med 1997, 157:913-919.
111. Moro P.A., Cassetti F., Giugliano G., et al. Hepatitis from greater celandine(Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 2009, 124:328-332.
112. Hardeman E., Van Overbeke L., Ilegems S., et al. Acute hepatitis induced by greater celandine(Chelidonium majus). Acta Gastroenterol Belg 2008, 71:281-282.
113. Stickel F., Pöschl G., Seitz H.K., et al. Acute hepatitis induced by greater celandine(Chelidonium majus). Scand J Gastroenterol 2003, 38:565-568.
114. Mahady G.B., Low Dog T., Barrett M.L., et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008, 15:628-638.
115. Whiting P.W., Clouston A., Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002, 177:440-443.
116. Lontos S., Jones R.M., Angus P.W., et al. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003, 179:390-391.
117. Levitsky J., Alli T.A., Wisecarver J., et al. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2005, 50:538-539.
118. Lynch C.R., Folkers M.E., Hutson W.R. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 2006, 12:989-992.
119. Pierard S., Coche J.C., Lanthier P., et al. Severe hepatitis associated with the use of black cohosh: a report of two cases and an advice for caution. Eur J Gastroenterol Hepatol 2009, 21:941-945.
120. Joy D., Joy J., Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. Climacteric 2008, 11:84-88.
121. Vannacci A., Lapi F., Gallo E., et al. Acase of hepatitis associated with long-term use of Cimicifuga racemosa. Altern Ther Health Med 2009, 15:62-63.
122. Naser B., Liske E., Teschke R. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2009, 190:99-100.
123. Cohen S.M., O'Connor A.M., Hart J., et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004, 11:575-577.
124. Guzman G., Kallwitz E.R., Wojewoda C., et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Rep Med 2009, 2009:918156.
125. Sperl W., Stuppner H., Gassner J., et al. Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea. Eur J Pediatr 1995, 154:112-116.
126. Yeong M.L., Swinburn B., Kennedy M., et al. Hepatic veno-occlusive disease associated with comfrey ingestion. JGastroenterol Hepatol 1990, 5:211-214.
127. Bach N., Thung S.N., Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989, 87:97-99.
128. Weston C.F., Cooper B.T., Davies J.D. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J 1987, 295:183.
129. Huxtable R.J., Luethy J., Zweifel U. Toxicity of comfrey-pepsin preparations. NEngl J Med 1986, 315:1095.
130. Ridker P.M., Ohkuma S., McDermott W.V., et al. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985, 88:1050-1054.
131. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. JHepatol 2003, 3:437-446.
132. Currie B.J., Clough A.R. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use?. Med J Aust 2003, 178:421-422.
133. Moulds R.F., Malani J. Kava: herbal panacea or liver poison?. Med J Aust 2003, 178:451-453.
134. Teschke R., Gaus W., Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003, 10:440-446.
135. Teschke R., Sarris J., Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 2011, 73:170-174.
136. Kraft M., Spahn T.W., Menzel J., et al. Fulminant liver failure after administration of the herbal antidepressant kavakava. Dtsch Med Wochenschr 2001, 126:970-972.
137. Strahl S., Ehret V., Dahm H.H., et al. Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 1998, 123:1410-1414.
138. Stevinson C., Huntley A., Ernst E. Asystematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 2002, 25:251-261.
139. Stickel F., Baumuller H.M., Seitz K., et al. Hepatitis induced by kava (Piper methysticum rhizoma). JHepatol 2003, 39:62-67.
140. Richardson W.N., Henderson L. The safety of kava - a regulatory perspective. BrJ Clin Pharmacol 2007, 64:418-420.
141. Teschke R., Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate?. Regul Toxicol Pharmacol 2011, 59:1-7.
142. Teschke R., Qiu S.X., Lebot V. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liver Dis 2011, 43:676-681.
143. Olsen L.R., Grillo M.P., Skonberg C. Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chem Res Toxicol 2011, 24:992-1002.
144. Yang L., Aronsohn A., Hart J., et al. Herbal hepatoxicity from Chinese skullcap: a case report. World J Hepatol 2012, 4:231-233.
145. Vassiliadis T., Anagnostis P., Patsiaoura K., et al. Valeriana hepatotoxicity. Sleep Med 2009, 10:935.
146. Cohen D.L., Del Toro Y. Acase of valerian-associated hepatotoxicity. JClin Gastroenterol 2008, 42:961-962.
147. Stadlbauer V., Weiss S., Payer F., et al. Herbal does not all mean innocuous: the sixth case of hepatotoxicity associated with Morinda citrifolia (noni). Am J Gastroenterol 2008, 103:2406-2407.
148. Millonig G., Stadlmann S., Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol 2005, 17:445-447.
149. Yuce B., Gulberg V., Diebold J., et al. Hepatitis induced by Noni juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip of the iceberg?. Digestion 2006, 73:167-170.
150. Stadlbauer V., Fickert P., Lackner C., et al. Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol 2005, 11:4758-4760.
151. Lopez-Cepero Andrada J.M., Lerma Castilla S., Fernandez Olvera M.D., et al. Hepatotoxicity caused by a Noni (Morinda citrifolia) preparation. Rev Esp Enferm Dig 2007, 99:179-181.
152. Yu E.L., Sivagnanam M., Ellis L., et al. Acute hepatotoxicity after ingestion of Morinda citrifolia (noni berry) juice in a 14-year-old boy. JPediatr Gastroenterol Nutr 2011, 52:222-224.
153. West B.J., Su C.X., Jensen C.J. Hepatotoxicity and subchronic toxicity tests of Morinda citrifolia (noni) fruit. JToxicol Sci 2009, 34:581-585.
154. West B.J., Jensen C.J., White L.D., et al. Adouble-blind clinical safety study of noni fruit juice. Pac Health Dialog 2009, 15:21-32.
155. Vallance W.B. Pennyroyal poisoning: a fatal case. Lancet 1955, 269(6895):850.
156. Sullivan J.B., Rumack B.H., Thomas H., et al. Pennyroyal oil poisoning and hepatotoxicity. JAMA 1979, 242:2873-2874.
157. Fatality and illness associated with consumption of pennyroyal oil-Colorado. MMWR Morb Mortal Wkly Rep 1978, 27:511-513.
158. Bakerink J.A., Gospe S.M., Dimand R.J., et al. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics 1996, 98:944-947.
159. Thomassen D., Slattery J.T., Nelson S.D. Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. JPharmacol Exp Ther 1990, 253:567-572.
160. Seeff L.B. Herbal hepatotoxicity. Clin Liver Dis 2007, 11:577-596.
161. Strader D.B., Navarro V.J., Seeff L.B. Hepatotoxicity of herbal preparations. Zakim and Boyer's hepatology: a textbook of liver disease 2012, 462-475. Saunders, Philadelphia. 6th edition. T.D. Boyer, M.P. Manns, A.J. Sanyal (Eds.).
162. Ahid S., Ait El Cadi M., Meddah B., et al. Atractylis gummifera: from poisoning to the analytic methods. Ann Biol Clin (Paris) 2012, 70:263-268.
163. Chou S.L., Chou M.Y., Kao W.F., et al. Bajiaolian poisoning-a poisoning with high misdiagnostic rate. Am J Emerg Med 2010, 28:85-89.
164. Hsu L.M., Huang Y.S., Tsay S.H., et al. Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang. JChin Med Assoc 2006, 69:86-88.
165. Itoh S., Marutani K., Nishijima T., et al. Liver injuries induced by herbal medicine, syo-saikoto (xiao-chai-hu-tang). Dig Dis Sci 1995, 40:1845-1848.
166. Kamiyama T., Nouchi T., Kojima S., et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997, 92:703-704.
167. Horowitz R.S., Feldhaus K., Dart R.C., et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996, 156:899-903.
168. McRae C.A., Agarwal K., Mutimer D., et al. Hepatitis associated with Chinese herbs. Eur J Gastroenterol Hepatol 2002, 14:559-562.
169. Picciotto A., Campo N., Brizzolara R., et al. Chronic hepatitis induced by Jin Bu Huan. JHepatol 1998, 28:165-167.
170. Woolf G.M., Petrovic L.M., Rojter S.E., et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 1994, 121:729-735.
171. Wai C.T., Tan B.H., Chan C.L., et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007, 27:465-474.